The Claim

In a 42-year-old woman with cystic fibrosis, obesity, and type 2 diabetes, 12 months of weekly 1 mg semaglutide treatment was associated with a 14.8% reduction in total body weight and clinically significant declines in absolute muscle mass, muscle strength, and bone mineral density at the spine and hip, despite structured exercise and nutritional interventions.

Source: Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon‐Like Peptide 1 Agonist: A Case Report

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
30score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In a 42-year-old woman with cystic fibrosis, obesity, and type 2 diabetes, taking 1 mg of semaglutide weekly for 12 months resulted in a 14.8% loss of total body weight and measurable decreases in muscle mass, muscle strength, and bone mineral density at the spine and hip, even with structured exercise and nutrition support.

See the scientific wording

In a 42-year-old woman with cystic fibrosis, obesity, and type 2 diabetes, 12 months of weekly 1 mg semaglutide treatment was associated with a 14.8% reduction in total body weight, accompanied by clinically significant declines in absolute muscle mass, muscle strength, and bone mineral density at the spine and hip, despite structured exercise and nutritional interventions.

Why this might work

A weight-loss drug reduces appetite and food intake, causing the body to burn muscle for energy. Less body weight means less force on bones, so bones break down faster than they rebuild. Even with exercise and good nutrition, muscle gets weaker and bones become fragile.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon‐Like Peptide 1 Agonist: A Case Report

    A woman with cystic fibrosis, obesity, and diabetes took a weight-loss drug called semaglutide for a year. She lost a lot of weight and her blood sugar improved, but she also lost muscle and bone strength—even though she exercised and ate well. The study shows the drug caused these side effects.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.